.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Follicular lymphoma remains a common yet complex malignancy. This disease often follows an indolent course but frequently results in repeated relapses. Consequently, patients often experience progressively shorter responses with each successive line of therapy. Recently, odronextamab follicular lymphoma treatment has emerged as a promising chemo-free approach for relapsed or refractory cases. This bispecific antibody specifically targets CD20 and CD3 to harness the patient's own immune system.
The clinical development of odronextamab centers on the pivotal ELM-1 and ELM-2 studies. These trials investigated its safety and anti-tumor activity in heavily pretreated patients. Specifically, the phase II ELM-2 trial reported an objective response rate (ORR) of approximately 80% in the follicular lymphoma cohort. Furthermore, over 70% of these patients achieved a complete response. These durable results led to its conditional approval by the European Medicines Agency (EMA). Moreover, researchers are now evaluating its performance in earlier lines of therapy via the OLYMPIA trial program.
The therapeutic mechanism involves simultaneously binding to CD20 on malignant B-cells and CD3 on T-cells. This dual engagement facilitates potent T-cell-mediated cytotoxicity against the lymphoma cells. Although the efficacy is high, clinicians must manage specific adverse events like cytokine release syndrome (CRS). Most cases of CRS occur early during treatment and are generally manageable with step-up dosing and prophylaxis. Additionally, ongoing studies like OLYMPIA-1 and OLYMPIA-5 are exploring combinations with agents like lenalidomide to improve outcomes further. Therefore, odronextamab represents a significant shift toward precision immunotherapy in hematological oncology.
Unlike rituximab, which is a monoclonal antibody, odronextamab is a bispecific antibody. It does not just mark cells for destruction; it actively pulls T-cells into direct contact with cancer cells to trigger a kill response.
Currently, regulatory approval focuses on relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. However, ongoing phase III trials are investigating its use in earlier and frontline settings.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Odronextamab, a novel bispecific antibody, is transforming the care of relapsed/refractory follicular lymphoma. Following its EMA approval, this review highlights its impressive efficacy in the ELM trials and explores its future role in earlier lines of therapy.
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
